Replies to post #21981 on Marker Therapeutics Inc (MRKR)

[TomP1]

I believe you are mixing up different trials. There is a distinction between those that are run by TPIV and those by Mayo. The extended ones are by Mayo. And the long-term data which will be published in the near future, is from a TPIV-trial.

[Marv79]

TPIV and Wilson tells you what you want to hear, they use the word soon to keep you hanging on until another sucker buys shares and they start all over again, shareholder turnover a key strategy in Wilson maintaining employment at 70 Years old! Further, MAYO is an academic institution and Wilson/Kenney finally admitted they have no influence with MAYO after a 13 year relationship. Do not believe a word these guys say, even perceived good news is bad like the amended trial for TPIV200. And finally the handful of faithful posters to afraid to cut losses and move on so they distort the reality trying to get people to hang on. The reality is Wilson is late again and has nothing for Q3 as promised and probably nothing for 2017. This is how it goes, first wave down to low $2's around $2.25 second wave to mid $1's about $1.35 to $1.40 and third wave under $1/share. Then Wilson gets fired and we recover, that is what is going to happen if Wilson stays around.